Spruce Biosciences ( (SPRB) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spruce Biosciences, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the company experiencing difficulties in completing certain required disclosures, which could not be resolved without unreasonable effort or expense. The company anticipates filing the report no later than fifteen days after the original deadline. Financially, Spruce Biosciences expects significant changes, including a 50% decrease in collaboration revenue and a high single-digit increase in loss from operations. Additionally, there is substantial doubt about the company’s ability to continue as a going concern due to a materially decreased cash balance. The notification was signed by CEO Javier Szwarcberg, M.D., MPH, who assured ongoing compliance efforts.
More about Spruce Biosciences
YTD Price Performance: -29.59%
Average Trading Volume: 366,835
Technical Sentiment Signal: Buy
Current Market Cap: $12.19M
See more insights into SPRB stock on TipRanks’ Stock Analysis page.